Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel + Prednisone Schedules in 2nd Line HRPC
NCT00268710Phase 2Completed
- Sponsor
- Sanofi
- Start
- Feb 2004
- Primary completion
- Mar 2006
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of docetaxel in prostate cancer (PCa) (2 arms), sponsored by Sanofi. Primary endpoint: Pain progression evaluated with the Present Pain Intensity scale form McGill-Melzack questionnaire. Started Feb 2004; status: completed.
02
Drugs
docetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00268710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00268710.